Congress Materials - Rheumatology Convergence Congress 2025
2025 Rheumatology Convergence Congress | Oct 24-29 | Chicago, IL
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
A Systematic Literature Review on the Economic Burden of Sjögren's Disease
Nora Sandorfi, Lisa Shea, Alexander Keenan, Elizabeth Adamson, Federico Zazzetti, Soumya Chakravarty, Donna Gotshall, Jyotika Gandhi, Sandip Ranjan, Esen Akpek
This document will be available on October 26th 2025
Biological Sex-Related Differences in Radiographic Progression and Relationship With Early Clinical Response: Post Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study in Biologic-Naive Participants with Active Psoriatic Arthritis Treated With Guselkumab
Dafna D. Gladman, Lihi Eder, Carlo Selmi, Philip J. Mease, Alexis Ogdie, Karissa Lozenski, Mohamed Sharaf, Emmanouil Rampakakis, Laura Pina Vegas, Laura Coates
This document will be available on October 26th 2025
Clinically Relevant Anti-Vaccine and Virus Antibodies in Patients with Sjogren’s Disease Treated with Nipocalimab: Post-Hoc Analysis of the DAHLIAS Study
Faye Yu, Eugene Myshkin, Jonathan J. Hubbard, Kim Campbell, Matthew Loza, Dessislava Dimitrova, Carolyn Cuff, Sheng Gao
This document will be available on October 26th 2025
Cluster Analysis of Socioeconomic and Environmental Determinants Modifying Activity, Chronicity and Clinical Manifestations of Systemic Lupus Erythematosus in the GLADEL 2.0 Cohort
Marco Martinez, Karen Roberts, Rosana Quintana, Marina Scolnik, Carmen Funes Soaje, Paula Alba, Veronica Saurit, Mercedes Garcia, Guillermo Ariel Berbotto, Inés Verónica Bellomio, Mario Eduardo Kerzberg, Graciela Noemi Gomez, Cecilia Pisoni, Vicente Juarez, Ana Malvar, Antonio Da Silva, Odirlei Monticielo, Henrique Mariz, Francinne Ribeiro, Eduardo Borba, Eloisa Bonfa, Edgard dos Reis-Neto, Iris Guerra Herrera, Maria Loreto Massardo, Gustavo Aroca-Martínez, Lorena Gómez Escorcia, Carlos Alberto Cañas, Gerardo Quintana-Lopez, Carlos Toro-Gutierrez, Mario Moreno Alvarez, Miguel Saavedra, Margarita Portela Hernández, Hilda Fragoso-Loyo, Luis H. Silveira, Ignacio García-De la Torre, Carlos Abud-Mendoza, Jorge Antonio Esquivel Valerio, Maria Isabel Acosta, Astrid Paats, Claudia S. Mora-Trujillo, Manuel Ugarte-Gil, Armando Calvo, Roberto Muñoz-Louis, Martin Rebella, Alvaro Danza, José Gomez-Puerta, Federico Zazzetti, Ashley Orillion, Guillermo Pons-Estel, Ingris del Pilar Pelaez Ballestas
This document will be available on October 26th 2025
Customized Therapy for SLE: How Disease Severity Influences the Use of Corticosteroids and Biologics in Patients with SLE in the Lupus Federated Data Network (LupusNet) and a US Claims Database
Ashley Orillion, Federico Zazzetti, Anna Sheahan, Clair Blacketer, Michel van Speybroeck, Sarah Gasman, Reyhan Sonmez, Erika Noss, Manuel Ugarte-Gil, Rocío Gamboa-Cárdenas, Víctor Pimentel-Quiroz, Kaleb Michaud, Patti Katz, Rangi Kandane-Rathnayake, Eric Morand, Worawit Louthrenoo, Alberta Hoi, Yi-Hsing Chen, Jiacai Cho, Laniyati Hamijoyo, Shue Fen Luo, Sandra Navarra, Mandana Nikpour, José María Pego-Reigosa, Iñigo Rúa-Figueroa, Zulema Plaza, María Galindo-Izquierdo, Julia Martínez Barrio, Jaime Calvo, Antonio Fernández-Nebro, Raúl Menor Almagro, Eva Gloria Tomero Muriel, Javier Narváez, Chetan S. Karyekar
This document will be available on October 26th 2025
Early Systemic and Skin Pharmacodynamic Effects of Icotrokinra in Participants with Moderate-to-Severe Plaque Psoriasis: Results Through Week 24 of the Phase 3, ICONIC-LEAD Study
Julianty Angsana, Marta Polak, Sharan Nischal, Elizabeth Chen, Deepika Balakrishna, Ching-Heng Chou, Christopher Sisk, Lynn Tomsho, Arun Kannan, Cynthia DeKlotz, Megan Miller, Joseph Cafone, Paul Newbold, Ya-Wen Yang, Monica Leung, Dawn Waterworth, Nina Sabins, Anna Perillo, Andreas Pinter, Robert Bissonnette
This document will be available on October 26th 2025
Effect of Gender and Follow-up Time in Damage Accrual: Data From a Latin America Lupus Cohort
Diana Fernandez, Rosana Quintana, Karen Roberts, Romina Nieto, Marina Scolnik, Carmen Funes Soaje, Cintia Otaduy, Veronica Saurit, Valeria Arturi, Guillermo Ariel Berbotto, Maria Constanza Bertolaccini, Mario Eduardo Kerzberg, Maria de los Angeles Gargiulo, Cecilia Pisoni, Ana Carolina Ralle, Joaquín Martinez Serventi, Ana Silva, Odirlei Monticielo, Henrique Mariz, Laíssa Cristina Alves Alvino, Eduardo Borba, Emily Figueiredo Neves Yuki, Edgard Torres dos Reis-Neto, Iris Guerra Herrera, Milena Mimica, Gustavo Aroca-Martínez, Antonio Iglesias-Gamarra, Carlos Alberto Cañas, Gerardo Quintana-Lopez, Carlos Toro-Gutierrez, Mario Moreno Alvarez, Olga-Lidia Vera-Lastra, Margarita Portela Hernández, Hilda Fragoso-Loyo, Luis H. Silveira, Yelitza Gonzalez Bello, Carlos Abud-Mendoza, Jorge Antonio Esquivel Valerio, Marcelo Barrios, Lourdes Carolina Vázquez, Magaly Alva Linares, Manuel Ugarte-Gil, Armando Calvo, Roberto Muñoz-Louis, Ana Carina Pizzarossa, Gonzalo Silveira, Federico Zazzetti, Ashley Orillion, Urbano Sbarigia, Guillermo Pons-Estel
This document will be available on October 26th 2025
Effect of Guselkumab and IL-17 Inhibitors on Work Productivity and Activity Impairment in Psoriatic Arthritis: 6-Month Results of the PsABIOnd Observational Study
Stefan Siebert, Mohamed Sharaf, Frank Behrens, Proton Rahman, Mitsumasa Kishimoto, Enrique R. Soriano, Emmanouil Rampakakis, László Köleséri, Karissa Lozenski, Ruben Queiro, Ennio Lubrano, Laure Gossec
This document will be available on October 26th 2025
Effectiveness and Tolerability of Guselkumab or TNF inhibitors as Second-Line Treatment After Receiving a TNF inhibitor as First-Line Therapy to Treat Active Psoriatic Arthritis: 52-Week Interim Data from the Manhattan Study
Rocio Gonzalez Molina, Beatriz Joven, Marta Llanes, Vanesa Hernandez, Manuel Jose Moreno, Elena Blanco, Carolina Marin, Lourdes Mateo, Meritxell Salles Lizarzaburu, Martina Steiner, Laura Nuño, Antonio Fernández-Nebro, Raúl Veroz González, Ana Urruticoechea-Arana, Evelin Cervantes, Emilio Giner, Lola Fernandez de la fuente Burson, Alba Erra, Oscar Camacho, Elisabet Garcia, Angeles Hernandez, Janire Malave, Laia Orpinell, Inmaculada Ros Vilamajo, Sonia Castro, Patricia Lopez Viejo, Luis Sarabia, Rosa María García Portales, Jorge Cabezon, Puerto Moreno Gil, Francisco Maceiras, Daniel Pielfort, Sabela Diaz-Castroverde, Manuel Cuervas-mons, Jose Pinto-Tasende, Santiago Muñoz, Julio Ramirez
This document will be available on October 26th 2025
Efficacy and Safety of Guselkumab in Patients with Active Psoriatic Arthritis and Inadequate Response and/or Intolerance to One Prior Tumor Necrosis Factor Inhibitor
Alexis Ogdie, Joseph F. Merola, Philip J. Mease, Christopher Ritchlin, Jose U. Scher, Kimberly Parnell Lafferty, Daphne Chan, Soumya Chakravarty, Wayne Langholff, Yanli Wang, Olivia Choi, Yevgeniy Krol, Alice Gottlieb
This document will be available on October 26th 2025
Efficacy and Safety of Icotrokinra, a Novel Targeted Oral Peptide (IL-23R-Inhibitor), in Adolescents With Moderate-to-Severe Plaque Psoriasis: Subgroup Analyses From a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (ICONIC-LEAD)
Lawrence Eichenfield, Ricardo Galimberti, Adelaide Hebert, Wen-Hui Wang, Jennifer Soung, Nina Magnolo, John Browning, Angela Moore, Mark Lebwohl, Dagmar Wilsmann-Theis, Joseph F. Merola, Georgios Kokolakis, Dariusch Mortazawi, Parbeer Grewal, Megan Miller, Joseph Cafone, Shu Li, Gigi Jiang, Fabio Nunes, Cynthia DeKlotz, Amy Paller
This document will be available on October 27th 2025
Feasibility of Extrarenal Systemic Lupus Erythematosus Disease Modification in GLADEL 2.0, a Latin American Cohort
Julián Barahona-Correa, Santiago Bernal-Macías, Daniel Fernández, Óscar Muñoz, Lucia Hernandez, Erika Susana Palacios Santillan, Laura Maurelli, Paula Alba, Verónica Saurit, Lucila García, María Emilia Sattler, Maria Constanza Bertolaccini, Marina Laura Micelli, Graciela Gómez, Micaela A. Cosatti, Ana Carolina Ralle, Joaquín Martinez Serventi, Ana Silva, Odirlei Monticielo, Ángela Luzia Branco Pinto Duarte, Laíssa Cristina Alves Alvino, Eduardo Borba, Eloisa Bonfa, Edgard dos Reis-Neto, Iris Guerra Herrera, Milena Mimica, Gustavo Aroca Martínez, Lorena Gómez Escorcia, Carlos Alberto Cañas, Gerardo Quintana-Lopez, Carlos Toro-Gutiérrez, José Maximiliano Martínez Pérez, Reyna Elizabeth Sánchez-Briones, Mario Pérez Cristóbal, Eduardo Martin-Nares, Yaneli Juárez-Vicuña, Ignacio García-Valladares, Rodrigo Ortiz Hernández, Jorge Antonio Esquivel Valerio, Maria Isabel Acosta, Astrid Paats, Jorge Cieza Calderón, Manuel Ugarte-Gil, Armando Calvo, Rodamin Ambiorix Alvarez Santana, Analía Cánepa, Carina Pizzarossa, Federico Zazzetti, Ashley Orillion, Cristina Drenkard
This document will be available on October 27th 2025
Humanistic Burden of Sjögren's Disease: A Systematic Review of Treatment Efficacy on Health-Related Quality-of-Life
Esen Akpek, Elizabeth Adamson, Lisa Shea, Federico Zazzetti, Soumya Chakravarty, Sandip Ranjan, Ravi Potluri, Alexander Keenan
This document will be available on October 27th 2025
Icotrokinra (ICO), a Novel Targeted Oral Peptide, in Patients (Pts) With Psoriatic Disease: Exploratory Assessments From a Phase 2 Psoriasis (PsO) Study Informing a Phase 3 Clinical Program in Psoriatic Arthritis (PsA)
Joseph F. Merola, Philip J. Mease, Laura Coates, Iain McInnes, Peter Nash, Alexis Ogdie, Lihi Eder, Mitsumasa Kishimoto, Anna Beutler, Konstantina Psachoulia, Shihong Sheng, Bei Zhou, Mehrdad Javidi, Chandni Valiathan, Charles Iaconangelo, Ya-Wen Yang, Arun Kannan, Chetan S. Karyekar, Tasneam Shagroni
This document will be available on October 26th 2025
Improvements in Patient Reported Outcomes Through 24 Weeks of Guselkumab Treatment in Participants with Active Psoriatic Arthritis and Inadequate Response and/or Intolerance to One Prior Tumor Necrosis Factor Inhibitor
Alice Gottlieb, Joseph F. Merola, Philip J. Mease, Christopher Ritchlin, Jose U. Scher, Kimberly Parnell Lafferty, Daphne Chan, Soumya Chakravarty, Wayne Langholff, Yanli Wang, Olivia Choi, Yevgeniy Krol, Alexis Ogdie
This document will be available on October 26th 2025
Influence of Sex on the Therapeutic Persistence of Guselkumab in Psoriatic Disease: A Retrospective National Cohort Study
Laure Gossec, Pascal Claudepierre, Arnaud Constantin, Denis Jullien, Samira Chaalal, Julie Baraut, Laure Cipiere, Laurène Gautier, Pierre Lemire, Thierry Passeron
This document will be available on October 27th 2025
Inhibition of Structural Damage Progression with Guselkumab, a Selective IL-23i, in Participants with Active PsA: Results Through Week 24 of the Phase 3b, Randomized, Double-Blind, Placebo-Controlled APEX Study
Philip J. Mease, Christopher Ritchlin, Laura Coates, Alexa P. Kollmeier, Bei Zhou, Yusang Jiang, Karen Bensley, Koeun Im, Rattandeep Batra, Soumya Chakravarty, Proton Rahman, Désirée Van Der Heijde
This document will be available on October 28th 2025
Persistence and Effectiveness Across PsA Patient Subgroups with Guselkumab and IL-17 Inhibitors: 6-Month Results of the PsABIOnd Observational Study
Laure Gossec, Mohamed Sharaf, Xenofon Baraliakos, Mitsumasa Kishimoto, Ruben Queiro, Ennio Lubrano, Emmanouil Rampakakis, László Köleséri, Karissa Lozenski, Enrique R. Soriano, Proton Rahman, Frank Behrens, Stefan Siebert
This document will be available on October 26th 2025
Phase 3 Results From an Innovative Trial Design of Treating Plaque Psoriasis Involving Difficult-to-Treat, High-Impact Sites With Icotrokinra, a Targeted Oral Peptide That Selectively Inhibits the IL-23–Receptor
Melinda J. Gooderham, Edward Lain, Robert Bissonnette, Yu-Huei Huang, Charles Lynde, Matthias Hoffmann, Joseph F. Merola, Eingun J. Song, Jessica H. Rubens, Amy M. DeLozier, Ming-Chun Hsu, Richard B. Warren
This document will be available on October 26th 2025
Real-World On-Label Treatment Persistence Through 24 Months in Biologic-Naïve and Biologic-Experienced Patients With Psoriatic Arthritis: Comparison of Guselkumab versus Subcutaneous Interleukin-17A Inhibitors
Philip J. Mease, Jessica A. Walsh, Timothy P. Fitzgerald, Soumya Chakravarty, Elizabeth Adamson, Bruno Emond, Carmine Rossi, Samuel Schwartzbein, Kana Yokoji, Yuxi Wang, Patrick Lefebvre, Dominic Pilon, Shikha Singla, Joseph F. Merola
This document will be available on October 28th 2025
Real-World On-Label Treatment Persistence Through 24 Months in Biologic-Naïve and Biologic-Experienced Patients With Psoriatic Arthritis: Comparison of Guselkumab Versus Subcutaneous Tumor Necrosis Factor Inhibitors
Philip J. Mease, Jessica A. Walsh, Timothy P. Fitzgerald, Soumya Chakravarty, Elizabeth Adamson, Bruno Emond, Carmine Rossi, Samuel Schwartzbein, Kana Yokoji, Yuxi Wang, Patrick Lefebvre, Dominic Pilon, Shikha Singla, Joseph F. Merola
This document will be available on October 27th 2025
Regional Variability in SLE Damage Accumulation by Disease Activity Across the Lupus Federated Data Network (LupusNet)
Manuel Ugarte-Gil, Sarah Gasman, Federico Zazzetti, Ashley Orillion, Anna Sheahan, Clair Blacketer, Michel van Speybroeck, Reyhan Sonmez, Erika Noss, Rocío Gamboa-Cárdenas, Víctor Pimentel-Quiroz, Kaleb Michaud, Patti Katz, Rangi Kandane-Rathnayake, Eric Morand, Worawit Louthrenoo, Alberta Hoi, Yi-Hsing Chen, Jiacai Cho, Laniyati Hamijoyo, Shue Fen Luo, Sandra Navarra, Mandana Nikpour, José María Pego-Reigosa, Iñigo Rúa-Figueroa, Zulema Plaza, Maria Galindo-Izquierdo, Julia Martínez Barrio, Jaime Calvo, Antonio Fernández-Nebro, Raúl Menor Almagro, Eva Gloria Tomero Muriel, Javier Narváez, Chetan S. Karyekar
This document will be available on October 28th 2025
Risk Factors for Pulmonary Manifestations in GLADEL 2.0, a Systemic Lupus Erythematosus Latin American Cohort
Luis Javier Cajas Santana, Sebastián Molina-Ríos, Lucia Hernández, Romina Nieto, Gricel Maita Romero, Nidia Noemí Merás, Veronica Gabriela Savio, Veronica Saurit, Valeria Arturi, Boris Kisluk, Inés Verónica Bellomio, Mario Eduardo Kerzberg, Nicolas Perez, Cecilia Pisoni, Vicente Juarez, Joaquín Martinez Serventi, Nélzio Silva, Odirlei Monticielo, Mariana Souza Pessoa de Luna, Laíssa Cristina Alves Alvino, Eduardo Borba, Luciana Parente Costa Seguro, Edgard dos Reis-Neto, Iris Guerra Herrera, Milena Mimica, Gustavo Aroca Martínez, Valentina Pérez Jiménez, Carlos Alberto Cañas, Gerardo Quintana-Lopez, Carlos Toro-Gutierrez, Rafael Ignacio López Martínez, Miguel Saavedra, Margarita Portela Hernández, Hilda Fragoso-Loyo, Luis H. Silveira, Yelitza Gonzalez Bello, Carlos Abud-Mendoza, Jorge Antonio Esquivel Valerio, Patricia Langjahr, Astrid Paats, Claudia S. Mora-Trujillo, Victor Pimentel-Quiroz, Carlos Bedia, Teresandris Polanco Mora, Martin Rebella, Alvaro Danza, Federico Zazzetti, Ashley Orillion, Guillermo Pons-Estel, Graciela Alarcón
This document will be available on October 26th 2025
Safety of Guselkumab in Inflammatory Bowel Disease Up to 1 Year: Integrated Safety Analysis of Phase 2 and 3 Studies in Crohn’s Disease and Ulcerative Colitis
Bruce E. Sands, Remo Panaccione, Silvio Danese, Julián Panés, Tadakazu Hisamatsu, Geert D’Haens, Rian Van Rampelbergh, Mobolaji Olurinde, Jacqueline Yee, Karissa Lozenski, Thomas Baker, Shadi Yarandi, Matthew Germinaro, Marion L. Vetter, Hewei Li, Mauricio Rosas Ballina, Jessica R. Allegretti, Anita Afzali, David T. Rubin
This document will be available on October 26th 2025
SPECTREM: Guselkumab Significantly Improves Patient Reported Outcomes at Week 16 in Participants With Low Body Surface Area, Moderate Psoriasis With Special Sites Involvement
Jennifer Soung, Virginie Kelly, Marni Wiseman, Adrian Rodriguez, Theodore Alkousakis, Olivia Choi, Daphne Chan, Katelyn Rowland, Linda Hou, Jenny Jeyarajah, Nastaran Abbarin, Elizabeth Skobelev, Sancharitha Ramji, James Krell, Max Sauder, David Adam
This document will be available on October 26th 2025
Systemic Lupus Erythematosus and Statins in GLADEL 2.0: Are Cardiovascular Risk Prevention Guidelines Being Followed?
Ileana C. Reynosa-Silva, Iris J. Colunga-Pedraza, Guillermina Harvey, Dionicio A. Galarza-Delgado, Jose R. Azpiri-Lopez, Fernanda M. Garcia-Garcia, Oscar Azael Garza-Flores, Marina Scolnik, Gisela Subils, Cintia Otaduy, Veronica Saurit, Valeria Arturi, Leonel Berbotto, Guillermo Pons-Estel, Luciana Gonzalez Lucero, Melissa Brenda Serna Góngora, Maria de los Angeles Gargiulo, Cecilia Pisoni, Maria Elena Crespo, Mónica Sánchez Guamán, Vitalina de Souza Barbosa, Andrese Aline Gasparin, Henrique Ataide Mariz, Francinne Ribeiro, Eduardo Borba, Edgard dos Reis-Neto, Iris Guerra Herrera, Maria Loreto Massardo, Gustavo Aroca Martínez, Carlos Alberto Cañas, Gerardo Quintana-Lopez, Carlos Toro-Gutierrez, Mario Moreno Alvarez, Miguel Saavedra, Margarita Portela Hernández, Hilda Fragoso-Loyo, Luis M. Amezcua-Guerra, Ignacio García-De la Torre, Jorge Isaac Velasco Santos, Jorge Antonio Esquivel Valerio, Jhonatan Losanto, Magaly Alva Linares, Manuel Ugarte-Gil, Katiuzka Zuñiga Corrales, Roberto Muñoz-Louis, Carina Pizzarossa, Gonzalo Silveira, Federico Zazzetti, Ashley Orillion, Gloria Vásquez
This document will be available on October 27th 2025
The Renal Activity Index for Lupus Identifies and Predicts Complete Renal Remission or Absence of Kidney Involvement in Systemic Lupus Erythematosus
Guillermo Pons-Estel, Rosana Quintana, Romina Nieto, Hermine Brunner, Marina Scolnik, Carmen Funes Soaje, Paula Alba, Veronica Saurit, Mercedes Garcia, Guillermo Ariel Berbotto, Inés Verónica Bellomio, Mario Eduardo Kerzberg, Graciela Gomez, Cecilia Pisoni, Vicente Juarez, Ana Malvar, Nélzio Silva, Odielei Monticielo, Henrique Mariz, Francinne Ribeiro, Eduardo Borba, Eloisa Bonfa, Edgard Torres dos Reis-Neto, Iris Guerra Herrera, Maria Loreto Massardo, Gustavo Aroca-Martínez, Lorena Gómez Escorcia, Carlos Alberto Cañas, Gerardo Quintana-Lopez, Carlos Toro-Gutierrez, Mario Moreno Alvarez, Miguel Saavedra, Margarita Portela Hernández, Hilda Fragoso-Loyo, Luis H Silveira, Ignacio García-De la Torre, Carlos Abud-Mendoza, Jorge Antonio Esquivel Valerio, Maria Isabel Acosta, Astrid Paats, Claudia S. Mora-Trujillo, Manuel Ugarte-Gil, Armando Calvo, Roberto Muñoz-Louis, Martin Rebella, Alvaro Danza, Federico Zazzetti, Ashley Orillion, Urbano Sbarigia, Bernardo A. Pons-Estel
This document will be available on October 27th 2025
VISIBLE Post-Inflammatory Pigmentation Journeys: Exploring the Impact of Pigmentation
Tarek Dawamne, Olivia Choi, Alison Tran, Jacob Beer, Katelyn Rowland, Theodore Alkousakis, Oyediran Adelakun, Elizabeth Skobelev, Sancharitha Ramji, Tony Ma, Daphne Chan, Jenna Lester
This document will be available on October 26th 2025
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.
